Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 17Plasma cell 15Other hematologic neoplasm 12Breast 6Dermatologic 5Myeloid 4Genitourinary 4CNS 3Endocrine 2Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 2Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

fludarabine phosphate 113Cyclophosphamide 97Whole-Body Irradiation 82Mycophenolic Acid 79fludarabine 74Tacrolimus 69Busulfan 68Azacitidine 62Peripheral Blood Stem Cell Transplantation 59Melphalan 48Cytarabine 48Antilymphocyte Serum 47Methotrexate 45Cyclosporine 45Filgrastim 39Imatinib Mesylate 37Granulocyte Colony-Stimulating Factor 37Decitabine 35nilotinib 34thymoglobulin 31ruxolitinib 29Thiotepa 27Stem Cell Transplantation 23Clofarabine 22Alemtuzumab 21Rituximab 19Dasatinib 19Cord Blood Stem Cell Transplantation 19sargramostim 17Sirolimus 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Panobinostat × Myeloid × Clear all
NCT00449761 2021-07-15

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Novartis

Phase 2 Terminated
27 enrolled 14 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00946647 2020-08-04

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Novartis

Phase 1/2 Completed
113 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00939159 2018-08-23

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 2 Terminated
17 enrolled 5 charts
Myeloid

Myelodysplastic Syndromes, Neoplasms

NCT00691938 2016-10-13

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Washington University School of Medicine

Phase 1/2 Completed
52 enrolled 18 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡